Clinical Trials Browser

Phase 2 × Active not recruiting × enasidenib × Clear all

NCT04203316 2026-01-09

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute